Tinjauan Sistematis: Peran Kultur Hanging Drop 3D terhadap Ekspresi OCT4 dan NANOG pada Sel Punca Mesenkimal Tali Pusat dengan Suplementasi PRP dan FBS
DOI:
https://doi.org/10.22225/amj.6.2.2026.437-449Keywords:
umbilical cord-derived mesenchymal stem cells, 3D hanging drop culture, platelet-rich plasma, fetal bovine serum, OCT4, NANOGAbstract
Abstract
Systematic Review: The Role of Three-Dimensional Hanging Drop Culture in OCT4 and NANOG Expression in Umbilical Cord-Derived Mesenchymal Stem Cells Supplemented with PRP and FBS
Umbilical cord-derived mesenchymal stem cells (UC-MSCs) have considerable potential in regenerative medicine due to their multipotent capacity, high proliferative ability, and self-renewal properties. Three-dimensional (3D) hanging drop culture has been shown to promote spheroid formation that closely mimics the in vivo microenvironment, thereby supporting stemness maintenance and enhancing the expression of pluripotency-related genes, such as OCT4 and NANOG. However, the use of Fetal Bovine Serum (FBS) as a culture supplement remains limited by concerns regarding immunogenicity and the potential transmission of biological contaminants, highlighting the need for xeno-free alternatives such as Platelet-Rich Plasma (PRP). This systematic review aimed to evaluate the effects of PRP and FBS supplementation on the biological characteristics of UC-MSCs cultured using the 3D hanging drop method. A literature search was conducted using PubMed, ScienceDirect (Elsevier), and Google Scholar databases for studies published between 2015 and 2025, employing keywords related to UC-MSCs, 3D hanging drop culture, PRP, FBS, OCT4, and NANOG. Eligible studies were critically analyzed based on methodological quality and relevance to the review objectives. The findings indicate that 3D hanging drop culture enhances spheroid formation, preserves cell viability, and increases the expression of stemness markers OCT4 and NANOG compared with conventional two-dimensional culture. Several studies also reported that PRP supplementation supports cell proliferation and viability while maintaining pluripotency-related gene expression at levels comparable to or higher than those achieved with FBS. These findings suggest that PRP represents a promising xeno-free alternative for maintaining the stemness of UC-MSCs and supporting their future clinical applications in regenerative medicine.
Keywords: umbilical cord-derived mesenchymal stem cells, 3D hanging drop culture, platelet-rich plasma, fetal bovine serum, OCT4, NANOG.
References
DAFTAR PUSTAKA
1. Yuan M, Hu X, Yao L, Jiang Y, Li L. Mesenchymal stem cell homing to improve therapeutic efficacy in liver disease. Stem Cell Res Ther. 2022 Dec;13(1):179. doi:10.1186/s13287-022-02858-4
2. He H, Takahashi A, Mukai T, Hori A, Narita M, Tojo A, et al. The Immunomodulatory Effect of Triptolide on Mesenchymal Stromal Cells. Front Immunol. 2021;12:686356. doi:10.3389/fimmu.2021.686356 PubMed PMID: 34484183; PubMed Central PMCID: PMC8415460.
3. Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells - current trends and future prospective. Biosci Rep. 2015 Apr 28;35(2):e00191. doi:10.1042/BSR20150025 PubMed PMID: 25797907; PubMed Central PMCID: PMC4413017.
4. Fang Y, Eglen RM. Three-Dimensional Cell Cultures in Drug Discovery and Development. SLAS Discov Adv Life Sci R D. 2017 Jun;22(5):456–72. doi:10.1177/1087057117696795 PubMed PMID: 28520521; PubMed Central PMCID: PMC5448717.
5. Nurhidayati A, Sukmawati D. Platelet-Rich Plasma as Xenofree-Growth Factor For Mesenchymal Stem Cells Culture. Ris Inf Kesehat. 2023 Dec 27;12(2):240. doi:10.30644/rik.v12i2.801
6. Bacakova L, Zarubova J, Travnickova M, Musilkova J, Pajorova J, Slepicka P, et al. Stem cells: their source, potency and use in regenerative therapies with focus on adipose-derived stem cells – a review. Biotechnol Adv. 2018 Jul;36(4):1111–26. doi:10.1016/j.biotechadv.2018.03.011
7. Hartono B. Sel Punca?: Karakteristik, Potensi dan Aplikasinya. J Kedokt Meditek. 2017 Oct 10. doi:10.36452/jkdoktmeditek.v22i60.1456
8. Berebichez-Fridman R, Montero-Olvera PR. Sources and Clinical Applications of Mesenchymal Stem Cells: State-of-the-art review. Sultan Qaboos Univ Med J SQUMJ. 2018 Dec 19;18(3):264. doi:10.18295/squmj.2018.18.03.002
9. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–7. doi:10.1080/14653240600855905
10. Kapa?czy?ska M, Kolenda T, Przyby?a W, Zaj?czkowska M, Teresiak A, Filas V, et al. 2D and 3D cell cultures – a comparison of different types of cancer cell cultures. Arch Med Sci. 2016. doi:10.5114/aoms.2016.63743
11. Jensen C, Teng Y. Is It Time to Start Transitioning From 2D to 3D Cell Culture? Front Mol Biosci. 2020 Mar 6;7:33. doi:10.3389/fmolb.2020.00033
12. Habanjar O, Diab-Assaf M, Caldefie-Chezet F, Delort L. 3D Cell Culture Systems: Tumor Application, Advantages, and Disadvantages. Int J Mol Sci. 2021 Nov 11;22(22):12200. doi:10.3390/ijms222212200
13. Huh D, Hamilton GA, Ingber DE. From 3D cell culture to organs-on-chips. Trends Cell Biol. 2011 Dec;21(12):745–54. doi:10.1016/j.tcb.2011.09.005
14. Antoni D, Burckel H, Josset E, Noel G. Three-Dimensional Cell Culture: A Breakthrough in Vivo. Int J Mol Sci. 2015 Mar 11;16(3):5517–27. doi:10.3390/ijms16035517
15. Kim JB. Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol. 2005 Oct;15(5):365–77. doi:10.1016/j.semcancer.2005.05.002
16. Langhans SA. Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning. Front Pharmacol. 2018 Jan 23;9:6. doi:10.3389/fphar.2018.00006
17. Bartosh TJ, Ylöstalo JH, Mohammadipoor A, Bazhanov N, Coble K, Claypool K, et al. Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties. Proc Natl Acad Sci. 2010 Aug 3;107(31):13724–9. doi:10.1073/pnas.1008117107
18. Cesarz Z, Tamama K. Spheroid Culture of Mesenchymal Stem Cells. Li RK, editor. Stem Cells Int. 2016 Jan;2016(1):9176357. doi:10.1155/2016/9176357
19. Choi JR, Yong KW, Choi JY. Effects of mechanical loading on human mesenchymal stem cells for cartilage tissue engineering. J Cell Physiol. 2018 Mar;233(3):1913–28. doi:10.1002/jcp.26018 PubMed PMID: 28542924.
20. YlÖstalo JH, Bartosh TJ, Coble K, Prockop DJ. Human Mesenchymal Stem/Stromal Cells Cultured as Spheroids are Self?activated to Produce Prostaglandin E2 that Directs Stimulated Macrophages into an Anti?inflammatory Phenotype. STEM CELLS. 2012 Oct;30(10):2283–96. doi:10.1002/stem.1191
21. Laschober GT, Brunauer R, Jamnig A, Fehrer C, Greiderer B, Lepperdinger G. Leptin receptor/CD295 is upregulated on primary human mesenchymal stem cells of advancing biological age and distinctly marks the subpopulation of dying cells. Exp Gerontol. 2009;44(1–2):57–62. doi:10.1016/j.exger.2008.05.013 PubMed PMID: 18573328.
22. Lee J, Abdeen AA, Kilian KA. Rewiring mesenchymal stem cell lineage specification by switching the biophysical microenvironment. Sci Rep. 2014 Jun 5;4(1):5188. doi:10.1038/srep05188
23. Cheng NC, Wang S, Young TH. The influence of spheroid formation of human adipose-derived stem cells on chitosan films on stemness and differentiation capabilities. Biomaterials. 2012 Feb;33(6):1748–58. doi:10.1016/j.biomaterials.2011.11.049 PubMed PMID: 22153870.
24. Kim E, Tae G. Direct reprogramming and biomaterials for controlling cell fate. Biomater Res. 2016;20:39. doi:10.1186/s40824-016-0086-y PubMed PMID: 27980804; PubMed Central PMCID: PMC5142385.
25. Baraniak PR, McDevitt TC. Scaffold-free culture of mesenchymal stem cell spheroids in suspension preserves multilineage potential. Cell Tissue Res. 2012 Mar;347(3):701–11. doi:10.1007/s00441-011-1215-5 PubMed PMID: 21833761; PubMed Central PMCID: PMC4149251.
26. Farrokhfar S, Tiraihi T, Movahedin M, Azizi H. Differential gene expression by lithium chloride induction of adipose-derived stem cells into neural phenotype cells. Iran J Basic Med Sci. 2020 Apr;23(4). doi:10.22038/ijbms.2020.41582.9820
27. van der Valk J, Bieback K, Buta C, Cochrane B, Dirks WG, Fu J, et al. Fetal Bovine Serum (FBS): Past - Present - Future. ALTEX. 2018;35(1):99–118. doi:10.14573/altex.1705101 PubMed PMID: 28800376.
28. Karina, Wahyuningsih KA, Sobariah S, Rosliana I, Rosadi I, Widyastuti T, et al. Evaluation of platelet-rich plasma from diabetic donors shows increased platelet vascular endothelial growth factor release. Stem Cell Investig. 2019 Dec;6:43–43. doi:10.21037/sci.2019.10.02
29. Pavlovic V, Ciric M, Jovanovic V, Stojanovic P. Platelet Rich Plasma: a short overview of certain bioactive components. Open Med. 2016 Jan 1;11(1):242–7. doi:10.1515/med-2016-0048
30. Suryani D, Pawitan JA, Lilianty J, Purwoko RY, Liem IK, Damayanti L. Comparison of fetal bovine serum and platelet-rich plasma on human lipoaspirate-derived mesenchymal stem cell proliferation. Med J Indones. 2013 Aug 22;146. doi:10.13181/mji.v22i3.583
31. Rubio-Azpeitia E, Andia I. Partnership between platelet-rich plasma and mesenchymal stem cells: in vitro experience. Muscle Ligaments Tendons J. 2019 Jan;04(01):52. doi:10.32098/mltj.01.2014.10
32. Amable PR, Carias RBV, Teixeira MVT, Da Cruz Pacheco Í, Corrêa Do Amaral RJF, Granjeiro JM, et al. Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther. 2013 Jun 7;4(3):67. doi:10.1186/scrt218
33. Sukmawati D, Junaidi H, Syaidah R. Human platelet-rich plasma as a biological stimulant for proliferation and differentiation of mesenchymal stem cells. Biomed India. 2021 Apr 1;41(2):168–73. doi:10.51248/.v41i2.777
34. Shi G, Jin Y. Role of Oct4 in maintaining and regaining stem cell pluripotency. Stem Cell Res Ther. 2010 Dec;1(5):39. doi:10.1186/scrt39
35. Jeter CR, Yang T, Wang J, Chao HP, Tang DG. Concise Review: NANOG in Cancer Stem Cells and Tumor Development: An Update and Outstanding Questions. Stem Cells Dayt Ohio. 2015 Aug;33(8):2381–90. doi:10.1002/stem.2007 PubMed PMID: 25821200; PubMed Central PMCID: PMC4509798.
36. Nichols J, Zevnik B, Anastassiadis K, Niwa H, Klewe-Nebenius D, Chambers I, et al. Formation of Pluripotent Stem Cells in the Mammalian Embryo Depends on the POU Transcription Factor Oct4. Cell. 1998 Oct;95(3):379–91. doi:10.1016/S0092-8674(00)81769-9
37. Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, et al. Functional Expression Cloning of Nanog, a Pluripotency Sustaining Factor in Embryonic Stem Cells. Cell. 2003 May;113(5):643–55. doi:10.1016/S0092-8674(03)00392-1
38. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, et al. Core Transcriptional Regulatory Circuitry in Human Embryonic Stem Cells. Cell. 2005 Sep;122(6):947–56. doi:10.1016/j.cell.2005.08.020
39. Rodda DJ, Chew JL, Lim LH, Loh YH, Wang B, Ng HH, et al. Transcriptional Regulation of Nanog by OCT4 and SOX2. J Biol Chem. 2005 Jul;280(26):24731–7. doi:10.1074/jbc.M502573200
40. Kim J, Chu J, Shen X, Wang J, Orkin SH. An Extended Transcriptional Network for Pluripotency of Embryonic Stem Cells. Cell. 2008 Mar;132(6):1049–61. doi:10.1016/j.cell.2008.02.039
41. Andia I, Maffulli N. Platelet-rich plasma for managing pain and inflammation in osteoarthritis. Nat Rev Rheumatol. 2013 Dec;9(12):721–30. doi:10.1038/nrrheum.2013.141
42. Sundman EA, Cole BJ, Fortier LA. Growth Factor and Catabolic Cytokine Concentrations Are Influenced by the Cellular Composition of Platelet-Rich Plasma. Am J Sports Med. 2011 Oct;39(10):2135–40. doi:10.1177/0363546511417792
43. Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020. Int J Mol Sci. 2020 Oct 21;21(20):7794. doi:10.3390/ijms21207794
44. Tseng TC, Hsieh FY, Dai NT, Hsu SH. Substrate-mediated reprogramming of human fibroblasts into neural crest stem-like cells and their applications in neural repair. Biomaterials. 2016 Sep;102:148–61. doi:10.1016/j.biomaterials.2016.06.020 PubMed PMID: 27341268.
45. Sensebé L, Gadelorge M, Fleury-Cappellesso S. Production of mesenchymal stromal/stem cells according to good manufacturing practices: a review. Stem Cell Res Ther. 2013 Sep;4(3):66. doi:10.1186/scrt217
46. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–7. doi:10.1080/14653240600855905
47. Dohan Ehrenfest DM, Andia I, Zumstein MA, Zhang CQ, Pinto NR, Bielecki T. Classification of platelet concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: current consensus, clinical implications and perspectives. Muscles Ligaments Tendons J. 2014 Jan;4(1):3–9. PubMed PMID: 24932440; PubMed Central PMCID: PMC4049647.
48. Murphy SV, Atala A. 3D bioprinting of tissues and organs. Nat Biotechnol. 2014 Aug;32(8):773–85. doi:10.1038/nbt.2958
49. Trounson A, McDonald C. Stem Cell Therapies in Clinical Trials: Progress and Challenges. Cell Stem Cell. 2015 Jul;17(1):11–22. doi:10.1016/j.stem.2015.06.007
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Muhammad Faishal Budi Utomo, Wahyunia L. Septiana, Sastia Winda Astuti, Helsy Junaidi
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
